Overview
Updated 14 Jul 2026
Geoffrey Shapiro, MD PHD, is Senior Vice President, Developmental Therapeutics, Dana-Farber Cancer Institute. The public record shows 2,055 publications with 58,071 citations (h-index 116), centered on Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy. It also documents an investigator role on 24 registered clinical trials, industry payments reported by 6 companies, 11 NIH-funded awards (1997–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 24 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 71 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 392.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 24 registered studies on ClinicalTrials.gov. The most recent:
- Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 1RecruitingNCT05687110 - Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 2RecruitingNCT05564377 - Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 2Active, not recruitingNCT05554367
Industry payments
Updated 14 Jul 2026
6 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- EMD Serono Research & Development Institute, Inc.Program year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
- Bayer HealthCare Pharmaceuticals Inc.Program year20214 payments
NIH funding
Updated 14 Jul 2026
11 NIH research awards on record, funded 1997–2026 per NIH RePORTER. The latest:
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTN
Dana-Farber Cancer Inst
FY2026$2,272,446UM1CA186709 - Macrophage-directed strategies for BRCA-associated breast cancer
Brigham and Women'S Hospital
FY2026$772,208R01CA307291
Congress activity
Updated 14 Jul 2026
277 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 4004: Identification of predictive biomarkers of USP1 inhibitor sensitivity using ovarian cancer organoid models
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.
Proceedings of the National Academy of Sciences of the United States of America
2026
Most-cited worksby citation count (OpenAlex)
- 01Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer4,506 citations2010
- 02Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer1,997 citations2014
- 03KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors1,696 citations2020
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
450 Brookline Avenue, Boston, MA 02215
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - BA
Biochemistry, Columbia University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massachusettsasco.wildapricot.org ↗
Editorial & leadership rolesjournal and society appointments
- Institute Physician
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Editor
Clinical Cancer Research (AACR journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacrjournals.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massachusettsasco.wildapricot.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massachusettsasco.wildapricot.org ↗
Secondary affiliationsappointments beyond the home institution
- Professor of Medicine
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Clinical Director
Center for DNA Damage and Repair, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Institute Physician
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- "Putting the Spotlight on Rare Cancers"
Dana-Farber newsroom feature
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/geoffrey-shapiro-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/geoffrey-shapiro-893a973
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Geoffrey-Shapiro
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Facebook
facebook.com/AllianceForClinicalTrialsInOncology/posts/video-from-geoffrey-shapiro-md-phd-at-dana-farber-talks-about-the-courage-of-cli/1364401031938379
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Facebook
facebook.com/danafarbercancerinstitute/posts/geoffrey-shapiro-md-phd-who-leads-dana-farbers-early-drug-development-center-tal/10156378808037937
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - LinkedIn
linkedin.com/posts/the-alliance-for-clinical-trials-in-oncology_video-from-geoffrey-shapiro-md-phd-activity-7369459441298993158-i6xD
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Nikhil Munshi, MD
Dana-Farber Cancer Institute
- 1,801
- publications
- 152
- h-index
- 8
- trials
Patrick Wen, MD
Dana-Farber Cancer Institute
- 1,915
- publications
- 146
- h-index
- 27
- trials
Irene Ghobrial, MD
Dana-Farber Cancer Institute
- 1,124
- publications
- 101
- h-index
- 16
- trials
Patrick Ott, MD
Dana-Farber Cancer Institute
- 616
- publications
- 82
- h-index
- 8
- trials